2552.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Jun 2024 @ 23:15):

Stats
Today's Volume	75 000.00
Average Volume	1.07M
Market Cap	1.47B
EPS	HKD0 ( 2024-03-27 )
Next earnings date	( HKD0 ) 2024-06-27
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-6.25
ATR14	HKD0.0120 (0.80%)

Hua Medicine Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hua Medicine Financials

Annual	2023
Revenue:	HKD76.61M
Gross Profit:	HKD37.37M (48.78 %)
EPS:	HKD-0.220

FY	2023
Revenue:	HKD76.61M
Gross Profit:	HKD37.37M (48.78 %)
EPS:	HKD-0.220

FY	2022
Revenue:	HKD17.60M
Gross Profit:	HKD7.69M (43.69 %)
EPS:	HKD-0.210

FY	2021
Revenue:	HKD0.00
Gross Profit:	HKD0.00 (0.00 %)
EPS:	HKD-0.340

Financial Reports:

No articles found.

Hua Medicine Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Hua Medicine

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.